A decade of ibrutinib for CLL with and without <i>TP53</i> aberration: final report on an investigator-sponsored phase 2 study
Andy Itsara(National Institutes of Health), Adrian Wiestner(National Institutes of Health), Laura Samples(University of Washington), Susan Soto(National Institutes of Health), Xin Tian(National Institutes of Health), Inhye E. Ahn(Dana-Farber Cancer Institute), Victoria Rogness(National Institutes of Health), Emily Tomasulo(National Institutes of Health), Clare Sun(National Heart Lung and Blood Institute), Hao‐Wei Wang(Fu Jen Catholic University), Thomas E. Hughes(National Institutes of Health), Mohammed Farooqui(National Institutes of Health), Jeanine Superata(National Institutes of Health), Pia Nierman(National Institutes of Health), Larisa Bezkorovaynaya(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 3
Related Papers
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
|Proceedings of the National Academy of Sciences|2003|1k
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
|Cancer Cell|2003|927
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
|Proceedings of the National Academy of Sciences|2013|519
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422